Cargando…

IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma

With the intensive therapeutic strategies, diffuse large B-cell lymphoma (DLBCL) is still a fatal disease due to its progressive characteristics. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulator that catalyzes the commitment step of the kynurenine pathway in the immune system, its aberrant ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Chengtao, Li, Mengzhen, Zhang, Lian, Sun, Feifei, Chen, Huimou, Xu, Yanjie, Lan, Yingxia, Zhang, Li, Lu, Suying, Zhu, Jia, Huang, Junting, Wang, Juan, Hu, Yang, Feng, Yanfen, Zhang, Yizhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237101/ https://www.ncbi.nlm.nih.gov/pubmed/35760783 http://dx.doi.org/10.1038/s41419-022-05021-2

Ejemplares similares

MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
por: Sun, Chengtao, et al.
Publicado: (2020)

ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma
por: Li, Mengzhen, et al.
Publicado: (2021)

Bioinformatics Analysis and Validation Identify CDK1 and MAD2L1 as Prognostic Markers of Rhabdomyosarcoma
por: Lu, Suying, et al.
Publicado: (2020)

Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients
por: Lu, Suying, et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Identification of prognostic immune-related genes in rhabdoid tumor of kidney based on TARGET database analysis
por: Chen, Huimou, et al.
Publicado: (2021)

KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis
por: Chen, Binbin, et al.
Publicado: (2022)

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children
por: Zhu, Jia, et al.
Publicado: (2021)

Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study
por: Lan, Yingxia, et al.
Publicado: (2023)

CHIC Risk Stratification System for Predicting the Survival of Children With Hepatoblastoma: Data From Children With Hepatoblastoma in China
por: Huang, Junting, et al.
Publicado: (2020)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Risk factors for totally implantable access ports-associated thrombosis in pediatric oncology patients
por: Lan, Yingxia, et al.
Publicado: (2023)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma
por: Sun, Chengtao, et al.
Publicado: (2019)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
por: Que, Yi, et al.
Publicado: (2021)

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
por: Zhu, Xiaoqin, et al.
Publicado: (2021)

Multimodal Treatment of Children With Sacrococcygeal Yolk Sac Tumor: Retrospective Analysis of Clinicopathology Characteristics and Relapse-free Survival
por: Zhu, Jia, et al.
Publicado: (2021)

Long‐term follow‐up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities
por: Zeng, Chenggong, et al.
Publicado: (2023)

Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma
por: Chen, Tingting, et al.
Publicado: (2022)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China
por: Hong, Ye, et al.
Publicado: (2023)

Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells
por: Egorova, Olga, et al.
Publicado: (2020)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

Ubiquitin receptors play redundant roles in the proteasomal degradation of the p53 repressor MDM2
por: Sparks, Alison, et al.
Publicado: (2022)

Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
por: Que, Yi, et al.
Publicado: (2023)

The RP-Mdm2-p53 Pathway and Tumorigenesis
por: Miliani de Marval, Paula L., et al.
Publicado: (2011)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Histological transformation from gastric mucosa-associated lymphoid tissue lymphoma to gastric diffuse large B-cell lymphoma
por: Li, Xiaowu, et al.
Publicado: (2017)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Heterogeneous Hydration of p53/MDM2 Complex
por: Guo, Zuojun, et al.
Publicado: (2014)

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
por: Luo, Qiuyun, et al.
Publicado: (2020)

Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis
por: Huang, Junting, et al.
Publicado: (2023)

Structural Basis of Competitive Recognition of p53 and MDM2 by HAUSP/USP7: Implications for the Regulation of the p53–MDM2 Pathway
por: Hu, Min, et al.
Publicado: (2006)

Detection of P53 and Mdm2 in vitiligo
por: Wiwanitkit, Viroj
Publicado: (2013)

Evolution of the p53-MDM2 pathway
por: Åberg, Emma, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6tpvvgnrb9kap1m61d624es9io